期刊文献+

microRNA-125b对人视网膜母细胞瘤多药耐药性影响的实验研究 被引量:1

Effects of microRNA-125b on multidrug resistance in human retinoblastoma
原文传递
导出
摘要 目的探讨microRNA-125b(miR-125b)在人视网膜母细胞瘤细胞中多药耐药的作用及其机制。设计实验研究。研究对象人视网膜母细胞瘤SO-RB50细胞。方法用RT-PCR方法检测miR-125b视网膜母细胞瘤细胞株SO-RB50和耐药细胞株SO-Rb50/VCR中的表达变化;化学合成的miR-125b过表达(miR-125mimic组)和抑制载体(miR-125inhibitor组)转染SO-Rb50细胞株,用MTT法和Annexin V-FITC法检测在药物长春新碱、依托泊苷和卡铂,依次作用上述转染细胞后,细胞增生力和细胞凋亡的变化;用蛋白印迹法检测miR-125b过表达和抑制表达后细胞株SO-RB50中MAGE-A/P53蛋白的表达变化。主要指标细胞存活率和细胞凋亡率。结果SO-Rb50/VCR组与SO-RB50组相比,miR-125b的表达显著增高(P=0.002);长春新碱、依托泊苷和卡铂依次作用于转染后的SO-RB50细胞株后,miR-125mimic组与miR-125inhibitor组相比,细胞存活率显著增高(P=0.000),细胞凋亡率显著下降(P=0.000),P53蛋白表达水平显著下降(P=0.001),MAGE-A蛋白表达水平显著增高(P=0.004)。结论在SO-RB50细胞中,下调miR-125b后提高肿瘤细胞对化疗药物敏感性,且miR-125b可能是通过MAGE-A/P53通路调控视网膜母细胞瘤多药耐药性。 Objective To explore the effects of microRNA-125 b(miR-125b) on the retinoblastoma multidrug resistance and to study its molecular mechanism of miR-125b on chemotherapy sensitivity.Design Experimental study.Participants The retinablastoma cell lines SO-RB50.Methods The expression of miR-125b was detected by real-time PCR in SO-RB50 cell line and SO-RB50/VCR cell line.The synthesized miR-125b mimic(miR-125 mimic group) and miR-125b inhibitor(miR-125 inhibitor group) was transfected into retinoblastoma SO-RB50 cell line.In addition,three chemotherapeutic drugs,including carboplatin,etoposide and vincristine,were used to treat the transfected SO-RB50 cell line respectively,in order to evaluate the sensitivity of RB cells.The cell proliferation and apoptosis were measured by MTT and Annexin V-FITC.The protein expression level of MGEA-A and P53 was detected in the transfected SO-RB50 cell line by Western blot.Main Outcome Measures The percentage of cell survival and the percentage of apoptotic cells to total cells.Results MiR-125 b was significantly up-regulated(P=0.000)in the SO-RB50/VCR cell line compared to that in the SO-RB50 cell line(P=0.000).It apparently promotes RB cell proliferation and suppresses cell apoptosis(P=0.000) in the miR-125 mimic group compared with that in the miR-125 inhibitor group treated by carboplatin,etoposide and vincristine respectively(P=0.000).The protein expression level of MAGE-A was higher significantly in the miR-125 mimic group than in the miR-125 inhibitor group(P=0.004).M eanwhile,the protein expression level of P53 was lower significantly in the miR-125 mimic group than in the miR-125 inhibitor group(P=0.001).Conclusion The SO-RB50 cell line inhibited the expression of miR-125b was sensitive to carboplatin.etoposide and vincristine,and furthermore miR-125b/MAGE-A/p53 axis may be conducive to enhancing the efficacies of chemotherapeutic treatments for RB.
作者 白淑玮 毕春潮 张广良 邵娟 许治国 Bai Shuwei;Bi Chunchao;Zhang Guangliang;Shao Juan;Xu Zhiguo(Department of Ophthalmology,Xi'an Fourth Hospital,Xi'an 710004,China;Department of Ophthalmology,Tongliao City Hospital,Tongliao 028000,Inner Mongolia,China)
出处 《眼科》 CAS 2020年第6期470-475,共6页 Ophthalmology in China
关键词 视网膜母细胞瘤 microRNA-125b MAGE-A/P53 多药耐药 retinoblastoma microRNA-125b MAGE-A/P53 multidrug resistance
  • 相关文献

参考文献4

二级参考文献22

  • 1Bai-Lin Wang, Hai-Ying Zhai, Bing-Yi Chen, Shu-Ping Zhai, Hai-Yan Yang, Xiao-Ping Chen, Wen-Tao Zhao and Lei Meng Guangzhou, China Third Department of Surgery, First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China,Depart- ment of Surgery, First People’s Hospital, Jining 272100, China ,Department of Surgery, General Hospital of PLA, Beijing 100853, China,and Hepatic Surgery Center, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.Clinical relationship between MDR1 gene and gallbladder cancer[J].Hepatobiliary & Pancreatic Diseases International,2004,3(2):296-299. 被引量:9
  • 2张浩,颜建华,吴中耀.化学减容治疗眼内期视网膜母细胞瘤[J].中国实用眼科杂志,2005,23(10):1051-1053. 被引量:7
  • 3高蕊,李彬.视网膜母细胞瘤化学治疗进展[J].国际眼科纵览,2006,30(2):140-142. 被引量:6
  • 4王卫东,陈正堂.Bcl-2/Bax比率与细胞“命运”[J].中国肿瘤生物治疗杂志,2007,14(4):393-396. 被引量:163
  • 5赵军阳.从R-E到IRC分级:视网膜母细胞瘤治疗观念的转变[J].眼科,2007,16(6):368-372. 被引量:17
  • 6Shields CI,, Lally SE, I,eahey AM, et al. Targeted retinoblastoma nlanag~nll~nl: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol, 2014. 25(5): 374-385. 被引量:1
  • 7Chia S, Gandhi S, Joy AA, et al. Targeted retinoblastoma manage- ment: when to use intravenous, intra-arteriaL periocular, and in- travitreal chemotherapy. Curr Opin Ophtilalmol, 2014, 25 (5): 374-385. 被引量:1
  • 8Tokunaga E, Oki E, Egashira A, et ai. Deregulation of tile Akt path- way in human cancer. Curl" Cancer Drug Targets, 2008, 8 (1): 27-36. 被引量:1
  • 9Zhang H, I,i B, Bai S, el al. Constitutively active Akl contributes to vincristine resistam~e in human retinoblastoma ,'ells. Can~'er Invest, 2010, 28(2): 156-165. 被引量:1
  • 10Mot G, Mtmtagna MK, Alvero AB. Modulatit~n ~f apop|osis to re- w~rse chemoresistance, Methods Mol Biol, 2008, 414: 1-12. 被引量:1

共引文献8

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部